Spectrum Pharmaceuticals Inc. (SPPI)

9.32
NASDAQ : Health Technology
Prev Close 9.44
Day Low/High 9.00 / 9.76
52 Wk Low/High 6.22 / 21.80
Avg Volume 747.90K
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 982.28M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spectrum Pharmaceuticals To Present Corporate Update At The Morgan Stanley Global Healthcare Conference In New York City On September 9th

Spectrum Pharmaceuticals To Present Corporate Update At The Morgan Stanley Global Healthcare Conference In New York City On September 9th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Interesting SPPI Put And Call Options For October 18th

Interesting SPPI Put And Call Options For October 18th

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

SPPI Crosses Above Key Moving Average Level

SPPI Crosses Above Key Moving Average Level

In trading on Monday, shares of Spectrum Pharmaceuticals Inc crossed above their 200 day moving average of $8.19, changing hands as high as $8.20 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 1.5% on the day.

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.

Spectrum Pharmaceuticals Reports 45% Sales Growth In The Second Quarter, Launches Fifth Product And Moves Closer To A Decision On A Potential Blockbuster

Spectrum Pharmaceuticals Reports 45% Sales Growth In The Second Quarter, Launches Fifth Product And Moves Closer To A Decision On A Potential Blockbuster

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial ...

Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of September 20th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of September 20th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning

Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning

Shares of Spectrum Pharmaceuticals (SPPI) are higher after being given accelerated approval for its lymphoma drug by the FDA.

FDA Grants Spectrum Pharmaceuticals Accelerated Approval Of Beleodaq™ (belinostat) For Injection

FDA Grants Spectrum Pharmaceuticals Accelerated Approval Of Beleodaq™ (belinostat) For Injection

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.

Spectrum Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SPPI

Spectrum Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SPPI

In trading on Tuesday, shares of Spectrum Pharmaceuticals Inc crossed above their 200 day moving average of $8.33, changing hands as high as $8.41 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 3.1% on the day.

First Week Of SPPI February 2015 Options Trading

First Week Of SPPI February 2015 Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the February 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

SPPI Crosses Above Key Moving Average Level

SPPI Crosses Above Key Moving Average Level

In trading on Monday, shares of Spectrum Pharmaceuticals Inc crossed above their 200 day moving average of $8.29, changing hands as high as $8.30 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 3.5% on the day.

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Spectrum Pharmaceuticals Completes Enrollment In Phase 2 Trial Of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) To Treat Chemotherapy-induced Neutropenia

Spectrum Pharmaceuticals Completes Enrollment In Phase 2 Trial Of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) To Treat Chemotherapy-induced Neutropenia

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and with a primary focus in Hematology and Oncology, today announced that the key ...

First Week of SPPI July 19th Options Trading

First Week of SPPI July 19th Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2014 Health Care Conference In Las Vegas On May 13th

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2014 Health Care Conference In Las Vegas On May 13th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Spectrum Pharmaceuticals Reports Financial Results For First Quarter 2014

Spectrum Pharmaceuticals Reports Financial Results For First Quarter 2014

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for...

Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

Spectrum Pharmaceuticals’ Pivotal Trial Of Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

Spectrum Pharmaceuticals’ Pivotal Trial Of Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal...

Spectrum Pharmaceuticals Promotes And Appoints Joseph Turgeon As President And Chief Operating Officer

Spectrum Pharmaceuticals Promotes And Appoints Joseph Turgeon As President And Chief Operating Officer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotion of...

RSI Alert: Spectrum Pharmaceuticals (SPPI) Now Oversold

RSI Alert: Spectrum Pharmaceuticals (SPPI) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spectrum Pharmaceuticals Inc Stock Downgraded (SPPI)

Spectrum Pharmaceuticals Inc Stock Downgraded (SPPI)

Spectrum Pharmaceuticals (Nasdaq:SPPI) has been downgraded by TheStreet Ratings from from a hold to sell.

Ratings Changes Today

Upgrades: CLMS, DNR, GBX, ORRF, PPSI, TCPC, YDKN Downgrades: ATRS, EXK, MGLN, PERY, SBS, SPPI, VICR Initiations: ALQA, CRRS, FNRG, ICLD, LBMH, PFIE, XXII, ZTS Read on to get TheStreet Quant Ratings' detailed report:

First Week of SPPI November 22nd Options Trading

First Week of SPPI November 22nd Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of SPPI May 17th Options Trading

First Week of SPPI May 17th Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)

Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spectrum Pharmaceuticals To Present Corporate Update At The 26th Annual ROTH Conference In Laguna Niguel On March 11th

Spectrum Pharmaceuticals To Present Corporate Update At The 26th Annual ROTH Conference In Laguna Niguel On March 11th

Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Spectrum Pharmaceuticals Reports Fourth And Full Year 2013 Financial Results

Spectrum Pharmaceuticals Reports Fourth And Full Year 2013 Financial Results

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for...

Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

TheStreet Quant Rating: D (Sell)